Treatment of motor fluctuations in Parkinson's disease: recent developments and future directions.

Ramirez-Zamora A, Molho E.

Expert Rev Neurother. 2014 Jan;14(1):93-103. doi: 10.1586/14737175.2014.868306. Review.

Stereopsis impairment is associated with decreased color perception and worse motor performance in Parkinson's disease.

Sun L, Zhang H, Gu Z, Cao M, Li D, Chan P.

Eur J Med Res. 2014 May 24;19:29. doi: 10.1186/2047-783X-19-29.

Application of an OCT data-based mathematical model of the foveal pit in Parkinson disease.

Ding Y, Spund B, Glazman S, Shrier EM, Miri S, Selesnick I, Bodis-Wollner I.

J Neural Transm (Vienna). 2014 Nov;121(11):1367-76. doi: 10.1007/s00702-014-1214-2.

Effects of communal exercise with visual and auditory feedback provided by a smart application on gait ability and fear of falling in Parkinson's disease patients.

Park YJ.

J Exerc Rehabil. 2014 Oct 31;10(5):286-90. doi: 10.12965/jer.140148.

SNCA variants rs2736990 and rs356220 as risk factors for Parkinson's disease but not for amyotrophic lateral sclerosis and multiple system atrophy in a Chinese population.

Guo XY, Chen YP, Song W, Zhao B, Cao B, Wei QQ, Ou RW, Yang Y, Yuan LX, Shang HF.

Neurobiol Aging. 2014 Dec;35(12):2882.e1-6. doi: 10.1016/j.neurobiolaging.2014.07.014.

Late stages of hematopoiesis and B cell lymphopoiesis are regulated by α-synuclein, a key player in Parkinson's disease.

Xiao W, Shameli A, Harding CV, Meyerson HJ, Maitta RW.

Immunobiology. 2014 Nov;219(11):836-44. doi: 10.1016/j.imbio.2014.07.014.

Effects of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide on blood-brain barrier and dopaminergic neurons of rats with lipopolysaccharide-induced Parkinson's disease.

Wu XL, Wang P, Liu YH, Xue YX.

J Mol Neurosci. 2014 May;53(1):1-9. doi: 10.1007/s12031-013-0175-5.

α-Synuclein ubiquitination and novel therapeutic targets for Parkinson's disease.

Rott R, Szargel R, Shani V, Bisharat S, Engelender S.

CNS Neurol Disord Drug Targets. 2014;13(4):630-7. Review.

Brain SPECT can differentiate between essential tremor and early-stage tremor-dominant Parkinson's disease.

Song IU, Park JW, Chung SW, Chung YA.

J Clin Neurosci. 2014 Sep;21(9):1533-7. doi: 10.1016/j.jocn.2013.11.035.

Neuroprotective effects of puerarin on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced Parkinson's disease model in mice.

Zhu G, Wang X, Wu S, Li X, Li Q.

Phytother Res. 2014 Feb;28(2):179-86. doi: 10.1002/ptr.4975.

Treatment and physiology in Parkinson's disease and dystonia: using transcranial magnetic stimulation to uncover the mechanisms of action.

Wagle Shukla A, Vaillancourt DE.

Curr Neurol Neurosci Rep. 2014 Jun;14(6):449. doi: 10.1007/s11910-014-0449-5. Review.

The neuropsychological assessment battery categories test as a measure of executive dysfunction in patients with Parkinson's disease and essential tremor: an exploratory study.

Benge J, Phillips-Sabol J, Phenis R.

Clin Neuropsychol. 2014;28(6):1008-18. doi: 10.1080/13854046.2014.950985.

Motor output variability, deafferentation, and putative deficits in kinesthetic reafference in Parkinson's disease.

Torres EB, Cole J, Poizner H.

Front Hum Neurosci. 2014 Oct 21;8:823. doi: 10.3389/fnhum.2014.00823.

Mapping track density changes in nigrostriatal and extranigral pathways in Parkinson's disease.

Ziegler E, Rouillard M, André E, Coolen T, Stender J, Balteau E, Phillips C, Garraux G.

Neuroimage. 2014 Oct 1;99:498-508. doi: 10.1016/j.neuroimage.2014.06.033.

Neuroprotective Potential of Peroxisome Proliferator Activated Receptor- α Agonist in Cognitive Impairment in Parkinson's Disease: Behavioral, Biochemical, and PBPK Profile.

Uppalapati D, Das NR, Gangwal RP, Damre MV, Sangamwar AT, Sharma SS.

PPAR Res. 2014;2014:753587. doi: 10.1155/2014/753587.